PRESS RELEASE published on 08/27/2026 at 18:59, 2 months 5 days ago Inside Information / Other news releases ABIONYX Pharma updates activity and cash position for H1 2026: revenue of €1.9M, cash balance of €26.9M before Research Tax Credits and grants. Company focuses on innovative therapies for sepsis Revenue Cash Position Innovative Therapies ABIONYX Pharma Activity Update
BRIEF published on 07/06/2026 at 20:05, 3 months 26 days ago ABIONYX: Details on Share Capital and Voting Rights Euronext Paris Share Capital Voting Rights AMF ABIONYX
BRIEF published on 07/06/2026 at 20:05, 3 months 26 days ago ABIONYX Monthly Voting Rights Update Euronext Paris Share Capital Voting Rights Financial Update ABIONYX Pharma
PRESS RELEASE published on 07/06/2026 at 20:00, 3 months 26 days ago Inside Information / Other news releases ABIONYX Pharma discloses monthly statement of total voting rights and shares. Company focuses on innovative medicines development with lipid science expertise Shares Total Voting Rights ABIONYX Pharma Innovative Medicines Lipid Science
BRIEF published on 07/06/2026 at 19:19, 3 months 26 days ago ABIONYX's Half-Yearly Review of the Liquidity Contract Liquidity Transactions TP ICAP Actions ABIONYX Pharma
BRIEF published on 06/30/2026 at 19:13, 4 months 1 day ago ABIONYX Pharma is expanding rapidly following its General Meeting ABIONYX Pharma Sepsis CER-001 General Assembly 2026 ApoA-I Platform
BRIEF published on 06/30/2026 at 19:13, 4 months 1 day ago ABIONYX Pharma Secures Funding to Advance Sepsis Treatment ABIONYX Pharma CER-001 Financial Funding Sepsis Treatment ApoA-I Platform
PRESS RELEASE published on 06/30/2026 at 19:08, 4 months 1 day ago Inside Information / Other news releases ABIONYX Pharma scales up operations after securing resources, focusing on value creation in inflammation and sepsis treatment. Updates on pivotal clinical trial, financial visibility, and scientific platform development Financial Resources Clinical Trial ABIONYX Pharma Sepsis Inflammation Treatment
BRIEF published on 06/18/2026 at 07:35, 4 months 13 days ago ABIONYX Pharma successfully completes its capital increase Capital Increase Clinical Trial Bond Financing Sepsis Fenja Capital
BRIEF published on 06/18/2026 at 07:35, 4 months 13 days ago ABIONYX Pharma Completes Successful EUR 33 Million Financing Capital Increase Bond Financing ABIONYX Pharma Fenja Capital Sepsis Research
Published on 10/30/2026 at 23:35, 2 days 7 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 7 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 11 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 15 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/02/2026 at 06:00, 42 minutes ago Wujiang Marks 90 Years Since Fei Xiaotong's Jiangcun Field Study
Published on 11/01/2026 at 10:35, 20 hours 7 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 1 day 1 hour ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 14 hours ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 2 days 7 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 2 days 7 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 12 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days 18 hours ago Capital increase through exercise of subscription rights
